ClinicalTrials.gg
CompletedNCT00092014FACTUpdated Aug 14, 2024

A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)

A Phase 3 interventional study of Alendronate and Risedronate 35 mg in Postmenopausal Osteoporosis, sponsored by Organon and Co. Completed. Open to female participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Sep 2002, registered Sep 2004).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,053
Allocation
Randomized
Ages
25 Years and older
Sex
Female
01

Study summary

This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis. The primary hypothesis for this study is that in postmenopausal women with osteoporosis, treatment with oral alendronate 70 mg once weekly will produce a mean percent increase from baseline in hip trochanter bone mineral density (BMD) at 12 and 24 months which is greater than that observed with oral risedronate 35 mg once weekly.

02

Conditions studied

  • Postmenopausal Osteoporosis
03

In context

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

This study's enrollment of 1,053 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.

Browse Osteoporosis, Postmenopausal studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with osteoporosis

Exclusion criteria

Exclusion Criteria:

  • Bilateral hip replacements
  • Esophageal abnormalities
  • Metabolic bone disease (example - Vitamin D deficiency)
  • Medications that would affect the breakdown or build-up of bone turnover
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,053 participants (actual)

Study arms

  • Experimental
    Alendronate 70 mg

    Alendronate sodium, 70 mg, orally once weekly for up to 24 months

    Drug: Alendronate · Dietary Supplement: Elemental Calcium · Dietary Supplement: Vitamin D · Drug: Risendronate placebo

  • Active comparator
    Risendronate 35 mg

    Risendronate, 35 mg, orally once weekly for up to 24 months

    Drug: Risedronate 35 mg · Dietary Supplement: Elemental Calcium · Dietary Supplement: Vitamin D · Drug: Alendronate placebo

Interventions

  • Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

    Also known as: MK-0217, FOSAMAX®

  • Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

    Also known as: Actonel®, Atelvia®

  • Dietary supplementElemental Calcium

    Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.

  • Dietary supplementVitamin D

    Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.

  • DrugRisendronate placebo

    Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

  • DrugAlendronate placebo

    Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

06

What researchers measure

Primary outcomes

  1. Mean percent change from baseline in hip trochanter bone mineral density (BMD) at 12 months

    Time frame: Baseline and 12 months

  2. Mean percent change from baseline in hip trochanter BMD at 24 months

    Time frame: Baseline and 24 months

Secondary outcomes

  1. Mean percent change from baseline in total hip, femoral neck, posteroanterior (PA) lumbar BMD at 12 months

    Time frame: Baseline and 12 months

  2. Mean percent change from baseline in total hip, femoral neck, posteroanterior (PA) lumbar BMD at 24 months

    Time frame: Baseline and 24 months

  3. Change from baseline in biochemical markers of bone turnover at 12 months

    Time frame: Baseline and 12 months

  4. Change from baseline in biochemical markers of bone turnover at 24 months

    Time frame: Baseline and 24 months

  5. Percent responders (>=0% and >=3% change from baseline in hip trochanter and lumbar spine BMD) at 12 months

    Time frame: 12 months

  6. Percent responders ((>=0% and >=3% change from baseline in hip trochanter and lumbar spine BMD) at 24 months

    Time frame: 24 months

  7. Number of participants who experienced one or more adverse events (AE)

    Time frame: Up to 24 months

  8. Number of participants who discontinued study medication due to an AE

    Time frame: Up to 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005 Jan;20(1):141-51. doi: 10.1359/JBMR.040920. Epub 2004 Sep 29. PubMed 15619680 ↗
  • Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE; Fosamax Actonel Comparison Trial investigators. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin. 2004 Dec;20(12):2031-41. doi: 10.1185/030079904x16768. Erratum In: Curr Med Res Opin. 2005 Feb;21(2):325. PubMed 15706659 ↗
  • Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006 Jul;91(7):2631-7. doi: 10.1210/jc.2005-2602. Epub 2006 Apr 24. Erratum In: J Clin Endocrinol Metab. 2007 Aug;92(8):3032. PubMed 16636120 ↗
  • Burnett-Bowie SM, Saag K, Sebba A, de Papp AE, Chen E, Rosenberg E, Greenspan SL. Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. J Clin Endocrinol Metab. 2009 Apr;94(4):1097-103. doi: 10.1210/jc.2008-1122. Epub 2009 Jan 13. PubMed 19141590 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2002 to primary completion in Apr 2004, 19 months.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 19 months is below that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2004
First posted
Sep 24, 2004
StartActual
Sep 1, 2002
Primary completionActual
Apr 1, 2004
CompletionActual
Apr 1, 2004
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00092014
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 24, 2004
Start date
Sep 1, 2002
Primary completion
Apr 1, 2004
Completion
Apr 1, 2004
Last update
Aug 14, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alendronate

Start the discussion